| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Non-cash stock option expense | - | 0 |
| Net loss | -3,888,087 | -2,634,009 |
| Depreciation and amortization | 2,165 | 1,443 |
| Operating right of use asset | 409 | -849 |
| Shares issued for services | - | 0 |
| Grants receivable | -84,712 | -42,731 |
| Prepaid expense | -124,160 | 265,761 |
| Accounts payable | 74,701 | 219,920 |
| Accrued expenses | -202,948 | -222,800 |
| Payroll liability | 19,567 | 62 |
| Net cash used in operating activities | -3,785,321 | -2,859,264 |
| Proceeds from issuance of common stock, preferred stock, and/or pre-funded warrants, net of issuance costs | 3,456,228 | 3,456,228 |
| Net cash provided by financing activities | 3,456,228 | 3,456,228 |
| Net cash used in investing activities | - | 0 |
| Net decrease in cash, cash equivalents | -329,093 | 596,965 |
| Cash and cash equivalents at beginning of period | 2,184,863 | - |
| Cash and cash equivalents at end of period | 1,855,770 | - |
LIPELLA PHARMACEUTICALS INC. (LIPO)
LIPELLA PHARMACEUTICALS INC. (LIPO)